Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.

Journal of clinical microbiology - 26 May 2020

Xu Lan, Oštrbenk Valenčak Anja, Poljak Mario, Arbyn Marc

Abstract excerpt

Hybribio's 14 High-Risk HPV with 16/18 genotyping real-time PCR (HBRT-H14) is a human papillomavirus (HPV) assay with approval from the China Food and Drug Administration that is widely used in China. VALGENT (VALidation of HPV GENotyping Tests) is an established framework for evaluating HPV tests' clinical performance relative to validated comparators. The aim of this study was to assess the clinical accuracy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to China
Share to Early Detection of Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotyping Techniques

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Sensitivity and Specificity

Share to Uterine Cervical Dysplasia

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32245832
DOI: 10.1128/JCM.00234-20
PMCID: PMC7269387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.PMID 32245832Read ↗

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China.Semantic proximity Read ↗

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT FrameworkSemantic proximity Read ↗

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.Semantic proximity Read ↗

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.Semantic proximity Read ↗

Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.Semantic proximity Read ↗

Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.Semantic proximity Read ↗

Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath mediumSemantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Diagnostic accuracy of extended HPV DNA genotyping and its application for risk-based cervical cancer screening strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.